spacer
spacer

PDBsum entry 5ivr

Go to PDB code: 
protein ligands metals Protein-protein interface(s) links
Hydrolase/inhibitor PDB id
5ivr

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
99 a.a.
Ligands
6EG
Metals
_CL ×4
Waters ×197
PDB id:
5ivr
Name: Hydrolase/inhibitor
Title: Crystal structure of HIV protease complexed with methyl n-[(1s)-1-[[2- [(3s)-3-[(4-aminophenyl)methylamino]-4-hydroxy- butyl]phenyl]carbamoyl]-2,2-diphenyl-ethyl]carbamate
Structure: Protease. Chain: a, b. Engineered: yes
Source: Human immunodeficiency virus 1. Organism_taxid: 11676. Gene: pol. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
1.50Å     R-factor:   0.193     R-free:   0.207
Authors: H.P.Su
Key ref: C.J.Bungard et al. (2016). Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group. Acs Med Chem Lett, 7, 702-707. PubMed id: 27437081 DOI: 10.1021/acsmedchemlett.6b00135
Date:
21-Mar-16     Release date:   18-May-16    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
Q77VV3  (Q77VV3_9HIV1) -  Protease (Fragment) from Human immunodeficiency virus 1
Seq:
Struc:
99 a.a.
99 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class: E.C.?
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

 

 
DOI no: 10.1021/acsmedchemlett.6b00135 Acs Med Chem Lett 7:702-707 (2016)
PubMed id: 27437081  
 
 
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.
C.J.Bungard, P.D.Williams, J.E.Ballard, D.J.Bennett, C.Beaulieu, C.Bahnck-Teets, S.S.Carroll, R.K.Chang, D.C.Dubost, J.F.Fay, T.L.Diamond, T.J.Greshock, L.Hao, M.K.Holloway, P.J.Felock, J.J.Gesell, H.P.Su, J.J.Manikowski, D.J.McKay, M.Miller, X.Min, C.Molinaro, O.M.Moradei, P.G.Nantermet, C.Nadeau, R.I.Sanchez, T.Satyanarayana, W.D.Shipe, S.K.Singh, V.L.Truong, S.Vijayasaradhi, C.M.Wiscount, J.P.Vacca, S.N.Crane, J.A.McCauley.
 
  ABSTRACT  
 
A novel HIV protease inhibitor was designed using a morpholine core as the aspartate binding group. Analysis of the crystal structure of the initial lead bound to HIV protease enabled optimization of enzyme potency and antiviral activity. This afforded a series of potent orally bioavailable inhibitors of which MK-8718 was identified as a compound with a favorable overall profile.
 

 

spacer

spacer